Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Monoclonal antibodies Stories

2013-09-26 20:21:49

EMERYVILLE, Calif., Sept. 26, 2013 /PRNewswire/ -- Trianni, Inc., a Californian biotechnology company, announced today the launch of its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates. Monoclonal antibodies are the most successful biologic therapeutics on the market. More than thirty have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of...

2013-09-25 08:29:22

Humanized Antibody for Orphan & Non-Orphan Ocular Disorders CLEVELAND, Sept. 25, 2013 /PRNewswire-USNewswire/ -- Today NovelMed Therapeutics announced preclinical study results for its lead compound in two models of AMD, a major cause of blindness affecting more than 2 million people in the United States. (Logo: http://photos.prnewswire.com/prnh/20130909/DC73243LOGO) Two independent preclinical investigations demonstrated that NovelMed's lead compound, an alternative pathway...

2013-09-24 04:22:08

Breakthrough Inovio DNA Technology Application Successfully Demonstrates Monoclonal Antibody Generation BLUE BELL, Pa., Sept. 24, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies. In this study in mice, a prototype monoclonal antibody construct encoding for an established anti-HIV monoclonal antibody...

2013-09-23 08:28:09

First and Only Anti-IL-12/23 Treatment Approved for Adult Patients Living with Psoriatic Arthritis HORSHAM, Pa., Sept. 23, 2013 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA(®) (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. It is estimated that more than two million people in the U.S. are living with psoriatic...

2013-09-23 08:28:04

Funding to study Lpathomab(TM) in diabetic neuropathic pain and diabetic neuropathy SAN DIEGO, Sept. 23, 2013 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in lipidomics-based therapeutics, announced receipt of a Notice of Grant Award from the National Institutes of Health (NIH). This $145,000 Phase 1 SBIR grant will support the study of Lpath's therapeutic monoclonal antibody, Lpathomab(TM), in animal models of diabetic neuropathic pain and diabetic neuropathy....

2013-09-19 16:26:13

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that Herb C. Cross will join the company as of September 23, 2013, and transition into the Chief Financial Officer role in coordination with Jeffrey H. Cooper, the company's current CFO. The company expects this transition will be completed in the October-November time frame. Mr. Cross was previously Chief Financial Officer of Affymax (Nasdaq: AFFY), a publicly traded...

2013-09-19 04:21:07

BREDA, the Netherlands and GHENT, Belgium, September 19, 2013 /PRNewswire/ -- arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody(TM) research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the...

2013-09-18 16:26:21

Human Safety and PK/PD Data from Phase 1 Study of KB001 Supports Ongoing Phase 2 Clinical Trial of KB001-A in Cystic Fibrosis SOUTH SAN FRANCISCO, Calif., Sept. 18, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced the publication of Phase 1 study results for KB001, a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF). Data from this initial single dose clinical study...

2013-09-17 04:22:16

BREDA, the Netherlands, and GHENT, Belgium, September 17, 2013 /PRNewswire/ -- SIMPLE Antibody(TM) with unique mode of action addressing c-Met positive tumors arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody(TM) product to enter the clinic this year. ARGX-111 is a...

2013-09-16 23:18:34

Reportbuyer.com just published a new market research report: PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022. London (PRWEB) September 16, 2013 PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet...